CA3071495A1 - Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed - Google Patents

Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed Download PDF

Info

Publication number
CA3071495A1
CA3071495A1 CA3071495A CA3071495A CA3071495A1 CA 3071495 A1 CA3071495 A1 CA 3071495A1 CA 3071495 A CA3071495 A CA 3071495A CA 3071495 A CA3071495 A CA 3071495A CA 3071495 A1 CA3071495 A1 CA 3071495A1
Authority
CA
Canada
Prior art keywords
cell
nucleic acid
car
expressed
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3071495A
Other languages
English (en)
French (fr)
Inventor
Martin PULE
Shaun Cordoba
Maria Stavrou
Vijay Peddareddigari
Paul Smith
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1712407.4A external-priority patent/GB201712407D0/en
Priority claimed from GBGB1806372.7A external-priority patent/GB201806372D0/en
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of CA3071495A1 publication Critical patent/CA3071495A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3071495A 2017-08-02 2018-08-01 Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed Abandoned CA3071495A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1712407.4A GB201712407D0 (en) 2017-08-02 2017-08-02 Cell
GB1712407.4 2017-08-02
GBGB1806372.7A GB201806372D0 (en) 2018-04-19 2018-04-19 Cell
GB1806372.7 2018-04-19
PCT/GB2018/052204 WO2019025800A1 (en) 2017-08-02 2018-08-01 CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE

Publications (1)

Publication Number Publication Date
CA3071495A1 true CA3071495A1 (en) 2019-02-07

Family

ID=63371717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3071495A Abandoned CA3071495A1 (en) 2017-08-02 2018-08-01 Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed

Country Status (7)

Country Link
US (1) US20210130775A1 (enExample)
EP (1) EP3662055A1 (enExample)
JP (2) JP2020530993A (enExample)
CN (1) CN111164203A (enExample)
AU (1) AU2018311345A1 (enExample)
CA (1) CA3071495A1 (enExample)
WO (1) WO2019025800A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
AU2020232789B2 (en) * 2019-03-06 2026-04-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2021028359A1 (en) * 2019-08-09 2021-02-18 Sangamo Therapeutics France Controlled expression of chimeric antigen receptors in t cells
EP4017510A4 (en) * 2019-08-20 2023-11-22 Senti Biosciences, Inc. CHIMERIC INHIBITOR RECEPTOR
CN120605327A (zh) * 2019-11-06 2025-09-09 贝勒医学院 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法
CA3176697A1 (en) * 2020-05-11 2021-11-18 Doughlas J. JOLLY Vectors and methods for in vivo transduction
GB202013466D0 (en) * 2020-08-27 2020-10-14 Inst De Medicina Molecular Joaeo Lobo Antunes Genetic construct
EP4455157A1 (en) * 2023-04-27 2024-10-30 Fundacion Publica Andaluza Progreso Y Salud M.P.- Fps Polynuceotide for t cell specific transgene expression
WO2025226608A1 (en) * 2024-04-22 2025-10-30 The Johns Hopkins University Immunotoxin-armored immune effector cells and uses thereof
WO2026085295A1 (en) * 2024-10-16 2026-04-23 The Cleveland Clinic Foundation Kynurenine responsive and degrading bacteria

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2126054T (pt) 2007-01-31 2016-10-12 Yeda Res & Dev Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
EP3858379A1 (en) * 2013-11-21 2021-08-04 Autolus Limited Cell
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
US11385233B2 (en) * 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
RU2744046C2 (ru) * 2014-03-05 2021-03-02 Отолус Лимитед ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) * 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201504840D0 (en) * 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
GB201507108D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
MX2017015239A (es) * 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
US10286092B2 (en) * 2015-08-25 2019-05-14 Ucl Business Plc Detecting a therapeutic cell
US11098283B2 (en) * 2015-08-25 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-Myb
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
JP7054924B2 (ja) * 2015-09-23 2022-04-15 サイトイミューン セラピューティクス， インコーポレイテッド 免疫療法のためのｆｌｔ３指向ｃａｒ細胞
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
WO2017075537A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
GB201609604D0 (en) * 2016-06-01 2016-07-13 Ucl Business Plc Cell
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Ltd Protein-based t-cell receptor knockdown
US20180064758A1 (en) * 2016-09-05 2018-03-08 Ucl Business Plc Chimeric antigen receptor
SG11201901757YA (en) * 2016-09-08 2019-03-28 Bluebird Bio Inc Pd-1 homing endonuclease variants, compositions, and methods of use
CA3042613A1 (en) * 2016-11-11 2018-05-17 Autolus Limited Chimeric antigen receptor
GB201621891D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Transcription system
WO2018193231A1 (en) * 2017-04-18 2018-10-25 Autolus Limited Cell
GB201707779D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
CA3063695A1 (en) * 2017-05-17 2018-11-22 Seattle Children's Hospital (Dba Seattle Children's Research Institute Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy
GB201716728D0 (en) * 2017-10-12 2017-11-29 Autolus Ltd Cell
JP7621795B2 (ja) * 2017-10-19 2025-01-27 セレクティス 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み
GB201718697D0 (en) * 2017-11-13 2017-12-27 Autolus Ltd Cell
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
GB201807862D0 (en) * 2018-05-15 2018-06-27 Ucl Business Plc Chimeric antigen receptor
WO2019220109A1 (en) * 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
GB201807870D0 (en) * 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
SG11202102781UA (en) * 2018-09-27 2021-04-29 Autolus Ltd Chimeric antigen receptor
GB201816522D0 (en) * 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
EP3934666A1 (en) * 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201906202D0 (en) * 2019-05-02 2019-06-19 Autolus Ltd Cell
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle

Also Published As

Publication number Publication date
CN111164203A (zh) 2020-05-15
JP2020530993A (ja) 2020-11-05
WO2019025800A1 (en) 2019-02-07
JP2023076572A (ja) 2023-06-01
US20210130775A1 (en) 2021-05-06
AU2018311345A1 (en) 2020-02-27
EP3662055A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
US20210130775A1 (en) Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
US12404316B2 (en) Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
US12612443B2 (en) Cell
US11981721B2 (en) Transposon-based transfection system for primary cells
JP2022058681A (ja) 受容体
RU2670147C1 (ru) Вектор экспрессии car и car-экспрессирующие т-клетки
CN112771166A (zh) 表达car的t细胞和car表达载体
AU2017380449A1 (en) Cell expressing a car and a transcription factor and its use
JP2023112191A (ja) 核酸構築物
CN115885038A (zh) 表达嵌合抗原受体的免疫活性细胞
WO2025134168A1 (en) Genetically modified immune cells for the treatment of tumors and autoimmune diseases
CN117242090A (zh) CAR T细胞疗法和IFNγ
KR20230079010A (ko) 듀얼 car-t 세포들
HK40105281A (en) Car t cell therapy and ifn gamma
HK40091903B (en) Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
HK40091903A (en) Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
WO2026044007A1 (en) Disruption of mbd6 in t cells to enhance immunotherapy
HK40006184A (en) Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
HK40006184B (en) Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
HK40003854A (en) Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
NZ737662B2 (en) Cell

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230203